Perrigo EBITDA 2011-2025 | PRGO
|
Perrigo Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $448 |
| 2023 | $514 |
| 2022 | $417 |
| 2021 | $719 |
| 2020 | $648 |
| 2019 | $567 |
| 2018 | $652 |
| 2017 | $1,021 |
| 2016 | $-1,567 |
| 2015 | $240 |
| 2015 | $931 |
| 2014 | $780 |
| 2013 | $839 |
| 2012 | $704 |
| 2011 | $593 |
|
Perrigo Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-06-30 | $134 |
| 2025-03-31 | $129 |
| 2024-12-31 | $202 |
| 2024-09-30 | $163 |
| 2024-06-30 | $56 |
| 2024-03-31 | $27 |
| 2023-12-31 | $71 |
| 2023-09-30 | $154 |
| 2023-06-30 | $151 |
| 2023-03-31 | $138 |
| 2022-12-31 | $130 |
| 2022-09-30 | $123 |
| 2022-06-30 | $73 |
| 2022-03-31 | $91 |
| 2021-12-31 | $119 |
| 2021-09-30 | $511 |
| 2021-06-30 | $-52 |
| 2021-03-31 | $141 |
| 2020-12-31 | $137 |
| 2020-09-30 | $175 |
| 2020-06-30 | $157 |
| 2020-03-31 | $179 |
| 2019-12-31 | $65 |
| 2019-09-30 | $156 |
| 2019-06-30 | $149 |
| 2019-03-31 | $197 |
| 2018-12-31 | $205 |
| 2018-09-30 | $-18 |
| 2018-06-30 | $201 |
| 2018-03-31 | $264 |
| 2017-12-31 | $266 |
| 2017-09-30 | $268 |
| 2017-06-30 | $255 |
| 2017-03-31 | $232 |
| 2016-12-31 | $-366 |
| 2016-09-30 | $-1,362 |
| 2016-06-30 | $289 |
| 2016-03-31 | $-129 |
| 2015-12-31 | $-563 |
| 2015-09-30 | $272 |
| 2015-06-30 | |
| 2015-03-31 | $247 |
| 2014-12-31 | $1,199 |
| 2014-09-30 | $137 |
| 2014-06-30 | |
| 2014-03-31 | $341 |
| 2013-12-31 | $1,042 |
| 2013-09-30 | $180 |
| 2013-06-30 | |
| 2013-03-31 | $291 |
| 2012-12-31 | $920 |
| 2012-09-30 | $157 |
| 2012-06-30 | |
| 2012-03-31 | $248 |
| 2011-12-31 | $871 |
| 2011-09-30 | $102 |
| 2011-06-30 | |
| 2011-03-31 | $199 |
| 2010-12-31 | $744 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $1.968B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $220.837B | 25.45 |
| EssilorLuxottica (ESLOY) | France | $169.692B | 0.00 |
| Boston Scientific (BSX) | United States | $151.950B | 34.75 |
| Stryker (SYK) | United States | $139.087B | 27.62 |
| Medtronic (MDT) | Ireland | $122.368B | 17.25 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.739B | 0.00 |
| Agilent Technologies (A) | United States | $42.361B | 27.42 |
| ResMed (RMD) | United States | $36.840B | 25.50 |
| GE HealthCare Technologies (GEHC) | United States | $33.440B | 15.99 |
| Koninklijke Philips (PHG) | Netherlands | $28.242B | 18.45 |
| Terumo (TRUMY) | Japan | $24.252B | 28.74 |
| Insulet (PODD) | United States | $22.953B | 71.24 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.539B | 10.94 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.204B | 0.00 |
| Baxter (BAX) | United States | $9.382B | 7.57 |
| Sunny Optical Technology (SNPTF) | China | $9.339B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.452B | 30.39 |
| Demant (WILYY) | Denmark | $7.496B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $3.539B | 10.78 |
| ICU Medical (ICUI) | United States | $3.536B | 22.45 |
| Haemonetics (HAE) | United States | $3.358B | 14.94 |
| Envista Holdings (NVST) | United States | $3.323B | 19.07 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.120B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.913B | 13.28 |
| LeMaitre Vascular (LMAT) | United States | $2.050B | 41.26 |
| Curaleaf Holdings (CURLF) | Canada | $1.896B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.837B | 18.35 |
| AtriCure (ATRC) | United States | $1.634B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.504B | 65.91 |
| QuidelOrtho (QDEL) | United States | $1.487B | 9.56 |
| Tilray Brands (TLRY) | Canada | $1.448B | 0.00 |
| Neogen (NEOG) | United States | $1.419B | 27.21 |
| Kestra Medical Technologies (KMTS) | United States | $1.418B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.291B | 18.71 |
| BioLife Solutions (BLFS) | United States | $1.254B | 372.00 |
| InMode (INMD) | Israel | $0.917B | 10.36 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.830B | 0.00 |
| Valneva SE (VALN) | France | $0.764B | 0.00 |
| Surmodics (SRDX) | United States | $0.585B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.517B | 17.80 |
| SNDL (SNDL) | Canada | $0.486B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.481B | 0.00 |
| Omeros (OMER) | United States | $0.469B | 0.00 |
| CeriBell (CBLL) | United States | $0.464B | 0.00 |
| Evolus (EOLS) | United States | $0.453B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.431B | 0.00 |
| Cerus (CERS) | United States | $0.317B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.303B | 0.00 |
| Brainsway (BWAY) | Israel | $0.288B | 50.60 |
| Canopy Growth (CGC) | Canada | $0.288B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.286B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.283B | 0.00 |
| High Tide (HITI) | Canada | $0.261B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.256B | 151.67 |
| Sanara MedTech (SMTI) | United States | $0.250B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.241B | 19.24 |
| Quanterix (QTRX) | United States | $0.234B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.224B | 0.00 |
| Organigram Global (OGI) | Canada | $0.221B | 0.00 |
| Owens & Minor (OMI) | United States | $0.220B | 2.21 |
| TriSalus Life Sciences (TLSI) | United States | $0.216B | 0.00 |
| Exagen (XGN) | United States | $0.209B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.195B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 16.16 |
| FitLife Brands (FTLF) | United States | $0.180B | 22.17 |
| OraSure Technologies (OSUR) | United States | $0.176B | 0.00 |
| Apyx Medical (APYX) | United States | $0.153B | 0.00 |
| Biote (BTMD) | United States | $0.129B | 5.21 |
| Jushi Holdings (JUSHF) | United States | $0.128B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.103B | 0.00 |
| Sharps Technology (STSS) | United States | $0.103B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.099B | 0.00 |
| MacroGenics (MGNX) | United States | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.092B | 13.33 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.057B | 33.00 |
| Nephros (NEPH) | United States | $0.046B | 33.31 |
| Cytosorbents (CTSO) | United States | $0.044B | 0.00 |
| Jin Medical (ZJYL) | China | $0.039B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Zynex (ZYXI) | United States | $0.035B | 0.00 |
| Bonk (BNKK) | United States | $0.033B | 0.00 |
| United-Guardian (UG) | United States | $0.029B | 14.77 |
| Modular Medical (MODD) | United States | $0.027B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| INLIF (INLF) | China | $0.010B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.001B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |